du Bois A, Rochon J, Lamparter C, Pfisterer J
Klinik für Gynäkologie and Gynäkologische Onkologie, HSK Wiesbaden, Germany.
Zentralbl Gynakol. 2005 Feb;127(1):18-30. doi: 10.1055/s-2005-836290.
To evaluate the relationship between hospital characteristics and quality of care and outcome in ovarian cancer in Germany.
This 2nd national survey in patients with histologically proven epithelial ovarian cancer diagnosed in the 3 (rd) quarter 2001 analyzed pattern of care in early (FIGO I-II A) and advanced (FIGO II B-IV) disease. We performed univariate and multivariate analysis of the role of hospital characteristics, like hospital-volume, participation in cooperative clinical studies, and hospital category (university vs central clinic vs. two lower categories in Germany) as prognostic factor.
165 hospitals documented 476 patients (= about one third of all patients diagnosed in Germany within one quarter). Patients treated in study-centres received more frequently standard care and showed superior survival (multivariate analysis including biologic prognostic factors: HR 1.71; 95 % CI 1.2-2.5; p = 0.007). 2-year-survival was 72 % and 64 % in study-centres and hospitals not participating in studies, respectively. Neither hospital category nor hospital-volume showed any significant impact on survival. Only analysis of surrogate parameters like pattern of care in early ovarian cancer revealed advantages related to hospital category. Furthermore, analysis of some surgical details revealed advantages for high-volume centres and hospital category.
Participation in clincal studies was the only transparent hospital characteristic with significant impact on prognosis of ovarian cancer. Study participation as criterion for quality of care should be included in counselling ovarian cancer patients and should help guiding selection of hospitals for primary therapy. All German hospitals with information about participation in cooperative clinical studies as well as in this quality assurance program are listed on the web.
评估德国医院特征与卵巢癌护理质量及预后之间的关系。
这项针对2001年第三季度确诊的组织学证实的上皮性卵巢癌患者的第二次全国性调查,分析了早期(国际妇产科联盟[FIGO] I-II A期)和晚期(FIGO II B-IV期)疾病的护理模式。我们对医院特征(如医院规模、参与合作临床研究情况以及医院类别[德国的大学医院、中心诊所与另外两类较低级别的医院])作为预后因素的作用进行了单因素和多因素分析。
165家医院记录了476例患者(约占德国一个季度内确诊的所有患者的三分之一)。在研究中心接受治疗的患者更频繁地接受标准护理,且生存率更高(包括生物学预后因素的多因素分析:风险比[HR] 1.71;95%置信区间[CI] 1.2 - 2.5;p = 0.007)。研究中心和未参与研究的医院的2年生存率分别为72%和64%。医院类别和医院规模对生存率均未显示出任何显著影响。仅对早期卵巢癌护理模式等替代参数的分析显示了与医院类别相关的优势。此外,对一些手术细节的分析显示了高规模中心和医院类别方面的优势。
参与临床研究是唯一对卵巢癌预后有显著影响的明确的医院特征。将参与研究作为护理质量的标准应纳入对卵巢癌患者的咨询中,并应有助于指导选择初级治疗的医院。所有提供参与合作临床研究以及参与此质量保证项目信息的德国医院都列在网上。